DRDeependra Kumar Rai

Deependra Kumar Rai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deependra Kumar Rai has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pattern and radiological severity of post-tuberculosis lung disease: A prospective observational study

    by Deependra Kumar Rai, Parul Sharma, Upasna Sinha, Dhruv Talwar, Sreyashi Pal, Swati, Shivam Sinha, Krishnakant Tripathi

  • Open Access

    Does Eosinophilia Mean Inhaled Corticosteroid Therapy in Obstructive Airway Disease? Revisiting a Treatable Trait across Asthma, Chronic Obstructive Pulmonary Disease, and Bronchiectasis

    by Deependra Kumar Rai

    A BSTRACT: Eosinophilic airway inflammation has emerged as an important biomarker in obstructive airway diseases and is increasingly used to guide inhaled corticosteroid (ICS) therapy. In asthma, eosinophilia is a well-established hallmark of type 2 inflammation and predicts favorable responsiveness to corticosteroids. In chronic obstructive pulmonary disease (COPD), blood eosinophil count has become a practical biomarker for identifying patients likely to benefit from ICS-containing regimens, particularly among those with frequent exacerbations. However, the interpretation of eosinophilia in bronchiectasis remains controversial, with limited evidence supporting routine ICS use, except in selected eosinophilic phenotypes or coexisting asthma. This viewpoint examines whether eosinophilia should automatically imply ICS therapy across obstructive airway diseases. We review the biological rationale, current evidence, limitations of eosinophils as biomarkers, disease-specific recommendations, and the balance between therapeutic benefits and adverse effects of ICS. While eosinophilia is a useful treatable trait, indiscriminate extrapolation of asthma paradigms to COPD and bronchiectasis may lead to overtreatment and increased risk of pneumonia, fungal infection, and microbiological colonization. Precision medicine approaches that integrate eosinophil counts with clinical phenotype, exacerbation history, and radiological findings are likely to optimize outcomes.

  • Ultrasonographic assessment of diaphragmatic dysfunction in COPD patients and its association with disease severity and exacerbation-An analytical cross - sectional study

    by Deependra Kumar Rai, Niraj Singh

    Background: The awareness of the idiaphragmatic dysfunction in patients with COPD by ultrasonography could lead to the early identification of respiratory muscle impairment. This study was conducted to evaluate diaphragmatic dysfunction in patients with COPD using ultrasonography and to assess its association with disease severity and exacerbation frequency. Method: An analytical cross-sectional study included consecutive stable COPD patients with at least one year of symptoms who presented to the outpatient department. Diaphragmatic Dysfunction (DD) was identified using the ultrasonographic cut-offs: excursion < 3.3 cm in females and < 4.1 cm in males during deep inspiration on the right side, or Thickening Fraction (DTf) < 20%. We also categorised DD as Restricted excursion only (E), Reduced thickening only (T), Both declined (TE), or No dysfunction (ND). Result: 220 patients were examined, with a mean age of 63.0 ± 10.3 years. The cohort was predominantly male (69.1%), and 59% were current or former smokers. Diaphragmatic dysfunction (DD) was present in 56.4% of subjects; of these, 28% had an isolated reduction in excursion, 1.6% % had an isolated reduction in thickness fraction, and 70.1% had a reduction in both thickness fraction and excursion. One-way ANOVA showed a statistically significant correlation between the GOLD group and DD, with a moderate effect size (F(2, 217) = 8.22, p = 0.001), indicating increased prevalence of dysfunction in more symptomatic or risk groups (e.g., Group E). DD was significantly correlated with the number of exacerbations (F(3, 216) = 5.79, p < 0.001). Conclusion: More than half of stable COPD patients have Diaphragmatic dysfunction & more occur in severe disease and in frequent exacerbators

  • Post-TB lung disease (PTLD): The silent aftermath of tuberculosis

    by Deependra Kumar Rai, V.K. Arora, Ranganath Ganga


  • Open Access

    Effectiveness and Safety of Glycopyrronium–Formoterol–Budesonide Triple Therapy in Chronic Obstructive Pulmonary Disease (AIR-FORCE): An Open-Label Multi-Centric Phase 4 Study

    by Anjali R. Nath, Adesh Kumar, Amit Suresh Bhate, Bharat Mehrotra, Deependra Kumar Rai, Vijay Kumar Barge, Divya Bhojwani, Sagar Bhagat, Sumit Bhushan, Saiprasad Patil, et al.

    Chronic obstructive pulmonary disease (COPD) is a major health burden in India with limited real-world data on triple inhaler therapy. This prospective, open-label, multi-center, single-arm, phase 4 study (October 2023–August 2024) assessed the effectiveness and safety of glycopyrronium/formoterol fumarate/budesonide (GFB) triple therapy, administered as metered-dose inhaler (MDI) or dry-powder inhaler (DPI), in Indian COPD patients. Symptomatic patients aged ≥40 years with minimum one exacerbation in the past year and receiving dual or monotherapy were included. GFB was delivered as MDI or DPI based on physician and patient preference. Primary outcomes were changes from baseline in trough forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and modified medical research council (mMRC) score over 24 weeks, with assessment of exacerbations, hospitalizations, rescue medication use, and safety. In 184 patients (70.65% male, mean age 53.7 years), GFB significantly improved FEV1, FVC, and mMRC scores. Eleven mild exacerbations were reported without hospitalization; 17.39% used rescue salbutamol largely in the first 4 weeks. GFB was well tolerated, with mild-to-moderate adverse events in 14.67%, and outcomes were comparable between MDI and DPI. Our findings support GFB as safe and effective treatment in real-world COPD management.

  • Open Access

    Bronchodilator reversibility and eosinophilic biomarkers in chronic obstructive pulmonary disease patients

    by H Ameet, Deependra K. Rai, Saurabh Karmakar, Somesh Thakur, Mala Mahto, Priya Sharma, Rajesh Yadav, Vatsal Gupta

    Background and Objectives: Chronic Obstructive Pulmonary Disease (COPD) is now one of the top three causes of death worldwide. Recently, increased focus has been on COPD patients displaying eosinophilic inflammation and asthma-like features of bronchial hyperreactivity and bronchodilator responsiveness. The objective of the study was to measure the proportion of chronic obstructive pulmonary disease patients with bronchodilator reversibility and to compare the eosinophilic biomarkers between the bronchodilator non-reversible and reversible groups. Materials and Methods: This hospital-based cross-sectional study included COPD patients who visited the Pulmonary Medicine OPD at the All-India Institute of Medical Sciences, Patna. Spirometry and eosinophilic biomarkers such as blood eosinophil, sputum eosinophil, FeNO, and serum IL-5 were measured. All statistical calculations were conducted using SPSS (Statistical Package for the Social Science 22 version (SPSS, Chicago, IL, United States). Results: A total of 160 COPD patients were included in the study. The mean age of the study population was 61 (±10) years. Males (68.1%) and non-smokers (55%) respectively were predominant. The prevalence of bronchodilator reversibility was found to be 32%. There was a significant difference in eosinophil biomarker levels, of sputum eosinophil count, peripheral eosinophil count, and FeNO levels between the bronchodilator non-reversible and bronchodilator reversible groups. Serum IL-5 levels were higher and more significant in GOLD group D patients. Conclusion: Eosinophils are crucial to the underlying inflammatory response in this subset of COPD patients, as evidenced by the observation that eosinophil biomarkers were significantly higher in COPD patients with bronchodilator reversibility. Also, sputum eosinophil levels had a better correlation in comparison to peripheral eosinophil level in this subset.


  • Open Access

    Sarcoidosis present as endobronchial lung mass: A rare case report with review of literature

    by Deependra Kumar Rai, Prashant Kumar

    Sarcoidosis is a multisystem granulomatous disorder of unknown etiology, primarily affecting the intrathoracic lymph node and the lung. The endobronchial involvement in sarcoidosis is not uncommon and may appear as nodules, cobblestoning, erythema, or plaque, but presentation as an endobronchial mass has been rarely described. We report here a 50-year-old gentleman who presented with nonproductive cough and dyspnea on exertion. Video bronchoscopy revealed a polypoid mass in the right lower lobe bronchus occluding the posterior basal segment, and bronchial biopsy revealed noncaseating granulomatous inflammation. Bronchoalveolar lavage (BAL) fluid was negative for tuberculosis, fungal infection, and malignancy. Mantoux test was negative, and serum angiotensin-converting enzyme was elevated. The diagnosis of sarcoidosis was made, and the patient was started on an oral corticosteroid. After treatment, the patient showed significant improvement in symptoms. This case report highlights a rare presentation of sarcoidosis as an endobronchial mass lesion. It is important to take a biopsy to differentiate from other common causes of endobronchial mass, such as malignancy and, rarely, tuberculosis. Sarcoidosis should be considered in a differential of the endobronchial mass lesion.


  • Open Access

    Palliative Care in Drug Resistance Tuberculosis: An Overlooked Component in Management

    by Deependra Kumar Rai, Priya Sharma

    Palliative care should be an important component in the management of drug resistant tuberculosis (DRTB); however, it is not given much importance. Even in the current scenario, many patients and their caregivers consider multidrug-resistant and extensively drug-resistant tuberculosis (TB) as a terminal illness and considering it almost as a death sentence, this group of patients also require palliative care. There is a misconception about considering palliative care as a treatment component in the terminal stage of an illness where curative treatment has no role in improving the survival of the patient. However, the real meaning of palliative care is to relieve suffering in all stages of the disease and is not limited to end-of-life care only. Palliative care in DRTB aims to improve the quality of life, intractable symptoms and physical, psychosocial and spiritual suffering of patients as well as their caregivers. There is an imminent need to train all TB healthcare workers regarding basic palliative care and integrate palliative care into the TB healthcare system.


  • Open Access

    Paradoxical reaction in peripheral lymph node tuberculosis: a review for its prevalence, clinical characteristics, and possible treatment

    by Deependra Kumar Rai, Surya Kant, Vatsal Bhushan Gupta

    The paradoxical reaction (PR) is a transient worsening following tuberculosis treatment and it is not uncommon in lymph node tuberculosis (LNTB). PR in LNTB maybe wrongly considered as treatment failure or relapse. This review was undertaken to address various aspects of PR associated with lymph node tuberculosis prevalence, underlying mechanism, clinical pattern, predictors, and possible treatment in an immunocompetent individual. A literature review was performed using various databases (PubMed, Scopus, Science Direct, and Google Scholar) to identify relevant articles for review. The prevalence of paradoxical reactions associated with LNTB varies from as low as 13.3% to as high as 35.3% PR may occur during antitubercular treatment or be reported even after completion of treatment called post-therapy PR. An onset of PR may occur within a month of therapy to even 12 months from the initiation of an anti-tubercular drug. Delayed hypersensitivity reaction and reduction in immune suppression is believed to be possible mechanism leading to a paradoxical reaction. PR in LNTB is characterized by either progression of pre-existing nodal enlargement or formation of abscess, sinus formation, or appearance of new nodal enlargement or rarely extra-nodal involvement. PR is a diagnosis of exclusion and may show granuloma, positive AFB smear, or positive GeneXpert but AFB culture is always negative. Younger age, lymph node size of equal to or more than 3 cm, female gender, unilateral lymphadenopathy, and those with positive AFB on initial examination are predictors for PR in peripheral LNTB. The majority of PR in LNTB have a mild course and are generally self-limited.


  • Open Access

    Crazy Paving Pattern Due to Invasive Pulmonary Aspergillosis: A Rare Case Report with Literature Review

    by Deependra K. Rai, Prashant Kumar

    The “crazy-paving” pattern at thin-section computed tomography of the lungs is characterized by ground-glass attenuation with superimposed interlobular septal thickening and intralobular lines, have various infective and non-infective causes described in literature but rarely described with aspergillus infection. We herein presented a very rare case of a crazy-paving pattern as a radiological manifestation of acute invasive pulmonary aspergillosis.